Scientific deep-dive

SURMOUNT-MAINTAIN: Can You Step Down Tirzepatide and Keep the Loss?

A randomized Lancet trial tested stepping tirzepatide down to 5 mg after 60 weeks at full dose. It kept more weight off than placebo and less than staying on full dose, and a quarter of people received rescue treatment.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·10 citations

Partly. A step-down to 5 mg of tirzepatide kept more weight off than stopping, and less than staying on the full dose. In SURMOUNT-MAINTAIN, a Lilly-funded randomized trial in The Lancet, adults who spent 60 weeks on 10 or 15 mg and then dropped to 5 mg stood at −16.6% from their starting weight at week 112, against −21.9% for those who kept their dose and −9.9% for those switched to placebo[1]. The averages hide a split: 25% of the 5 mg group regained enough to receive rescue treatment, compared with 8% on the full dose and 67% on placebo[1].

How the trial was built

Earlier tirzepatide research asked whether to continue or stop. This trial added the middle option. It ran at 20 US sites for 112 weeks: 60 weeks of open-label treatment at the maximum tolerated dose, 10 or 15 mg, followed by 52 double-blind weeks[1]. Of 441 people who started, 378 were randomized 3:3:2 at week 60: 140 to keep their dose, 144 to reduce to 5 mg and 94 to placebo[1]. So the comparison applies to people who were still in the study after more than a year on a high dose, a group selected for staying on treatment.

The people enrolled had a mean starting weight of 113.8 kg and a mean BMI of 40.1; 65% were female and 67% were White[1]. The design paper lists type 2 diabetes as an exclusion, so these results do not speak directly to people with diabetes[2]. From week 84, participants who had regained more than 50% of their lost weight could receive rescue tirzepatide[1]. One wrinkle: the 2025 design paper described the primary endpoint as percent maintenance of weight reduction among people who reached a plateau, while the Lancet abstract reports percent change from baseline, so the two descriptions differ[1][2].

What happened at week 112

Both tirzepatide arms beat placebo. The estimated difference was −12.0 percentage points for the full dose (95% CI −13.8 to −10.1) and −6.6 for 5 mg (95% CI −8.3 to −5.0), with p<0.0001 for all comparisons, and 91% of randomized participants completed the study[1]. The table sets out each arm.

SURMOUNT-MAINTAIN at week 112 (Horn 2026, The Lancet)
MeasureStay on 10 or 15 mgReduce to 5 mgSwitch to placebo
Randomized14014494
Weight change from baseline−21.9%−16.6%−9.9%
95% CI−23.5 to −20.3−18.0 to −15.1−11.1 to −8.8
Difference from placebo−12.0 points−6.6 pointsn/a
Received rescue tirzepatide11 of 138 (8%)35 of 142 (25%)60 of 90 (67%)

On the trial’s average starting weight, those percentages work out to roughly 25 kg, 19 kg and 11 kg below baseline. That is our arithmetic from the published means, offered only for scale[1]. The gap between full dose and 5 mg is about 5 percentage points, or about 6 kg at that starting weight. The abstract reports each dose against placebo and gives no direct 5 mg versus full-dose estimate, so we would not treat 5 points as a tested head-to-head figure. It also omits weight at week 60, which means the regain since the dose change cannot be calculated from the abstract[1].

Why the rescue numbers matter as much as the averages

A mean of −16.6% suggests that everyone landed somewhere near it. The rescue data say otherwise. One in four people who stepped down received rescue tirzepatide, which was open only to those who had regained more than half of their lost weight, during the trial’s final 28 weeks[1]. The authors’ own conclusion is hedged: reducing to 5 mg “might provide a valuable alternative to discontinuation, although individuals’ treatment response might vary”[1].

The rescue rule also shapes the headline figures. The primary analysis assumed that people who started rescue gained no further benefit from their assigned treatment[1]. That is a reasonable way to keep rescue from flattering an arm, but it means the placebo figure in particular is a modeled estimate for a group in which two-thirds were restarted on the drug. It should not be read as what would happen to someone who stops and never restarts. For that, the regain data after stopping tirzepatide are the closer guide.

How it lines up with earlier tirzepatide trials

SURMOUNT-4 randomized people to continue or stop after a 36-week lead-in. Those who continued reached −25.3% from baseline at week 88, and those on placebo −9.9%[3]. SURMOUNT-1 started people on fixed doses from the outset: at 72 weeks, the 5 mg group was at −15.0%, the 10 mg group at −19.5% and the 15 mg group at −20.9%[4]. In the three-year analysis of SURMOUNT-1 participants with prediabetes, the figures at 176 weeks were −12.3%, −18.7% and −19.7%[5].

Tirzepatide trials side by side. Designs and populations differ, so read across with care.
TrialWhat people didTimepointWeight change from baseline
SURMOUNT-MAINTAINReduce to 5 mg after 60 weeks at 10 or 15 mgWeek 112−16.6%
SURMOUNT-MAINTAINStay on 10 or 15 mgWeek 112−21.9%
SURMOUNT-4Stay on 10 or 15 mg after a 36-week lead-inWeek 88−25.3%
SURMOUNT-4Switch to placebo after a 36-week lead-inWeek 88−9.9%
SURMOUNT-15 mg from the startWeek 72−15.0%
SURMOUNT-1, prediabetes group5 mg from the startWeek 176−12.3%

These are separate trials with different lead-ins, and the SURMOUNT-1 three-year figures come from people with prediabetes, so none of this is a formal comparison. It raises a question the 52-week maintenance window cannot answer: does a step-down result hold in year three or four? On fixed 5 mg, the prediabetes group had lost less at 176 weeks (−12.3%) than the whole SURMOUNT-1 population had at 72 weeks (−15.0%)[4][5]. Some drift also shows up on continued treatment at any dose. A post hoc SURMOUNT-1 analysis of adherent participants with prediabetes found mean regain from lowest weight to week 176 of 3.8 kg, 4.4 kg and 3.7 kg on 5, 10 and 15 mg, with 70% regaining less than 5%[6].

What the trial leaves open

  • Doses between 5 mg and full dose. The trial tested 5 mg only[1]. It offers no data on stepping from 15 mg to 10 mg or 7.5 mg, a common question addressed in our Zepbound maintenance dose review.
  • Who does well at 5 mg. The abstract does not name predictors of holding weight on the lower dose, so we make no claim about them[1].
  • Whether side effects improve after stepping down. The abstract says gastrointestinal events were mostly mild to moderate and mostly occurred during dose escalation, without arm-by-arm rates for the maintenance period[1].
  • Independent replication. Lilly funded the trial, and 7 of the 13 authors are Lilly employees and shareholders[1].
  • Tapering by other schedules. A 2026 systematic review of weight regain after stopping these drugs concluded that evidence for tapering and other transition strategies “remains limited”[8].

Going below 5 mg, or changing drugs

The Zepbound label lists 5 mg, 10 mg and 15 mg as maintenance doses for weight reduction and long-term maintenance, and says plainly that the 2.5 mg dose is for starting treatment[9]. A non-randomized Japanese cohort of 112 adults compared 2.5 and 5 mg and reported −15.3% and −16.1% at six months[10]. Those participants were new to treatment, with a mean BMI of 30.8, and chose their dose through shared decision-making, so the study says little about stepping down after long use at a high dose[10].

Another route is switching to a pill. In ATTAIN-MAINTAIN, people who had taken tirzepatide in SURMOUNT-5 and reached a weight plateau were randomized to daily orforglipron or placebo. At week 52 the orforglipron group had maintained an estimated 74.7% of their weight reduction, against 49.2% on placebo[7]. That trial measured the share of lost weight kept, and had no arm that stayed on an injection, so it cannot be ranked against the 5 mg result[7].

What to raise with a prescriber

Our broader guide to GLP-1 step-down protocols covers the wider class. For tirzepatide specifically, these points follow from the trial:

  • Why you want to step down. The label says that if a maintenance dose is not tolerated, a lower one can be considered[9]. If the concern is cost or a wish to take less drug rather than side effects, it may help to say so, since the trial suggests the average trade-off is some weight[1].
  • A regain threshold agreed in advance. The trial used regain above 50% of lost weight as its trigger for rescue[1]. That was a research rule and not a clinical standard, but setting some number ahead of time gives both of you something to act on.
  • How you will monitor. Rescue in the trial began at week 84, 24 weeks after the dose change[1]. Ask how often weight and any related health markers should be checked once the dose drops.
  • Your health conditions. The label lists only 10 mg or 15 mg as maintenance doses for obstructive sleep apnea, so a person treated for that condition has a different question to ask[9]. People with type 2 diabetes were not studied in this trial[2].

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

It has been tested, and 5 mg is a labeled maintenance dose for weight management. In SURMOUNT-MAINTAIN, people who went from 10 or 15 mg down to 5 mg kept more weight off than people switched to placebo, but less than people who stayed on their dose. Whether it suits you is a decision to make with your prescriber.
The trial abstract reports weight from the original baseline and not from the point of the dose change. At week 112 the 5 mg group averaged 16.6% below baseline, compared with 21.9% on the full dose. A quarter of the 5 mg group received rescue treatment after regaining more than half of their lost weight, so individual results varied.
On average, yes, in this one randomized trial. People on 5 mg averaged 16.6% below their starting weight at week 112, against 9.9% for those on placebo, and 25% received rescue treatment compared with 67%. The trial lasted 52 weeks after the dose change and was funded by the manufacturer.
The Zepbound label says the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose, and SURMOUNT-MAINTAIN did not test it. A small Japanese study looked at 2.5 mg in people new to the drug, which is a different situation from stepping down after long use at a high dose.

References

  1. 1.Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, Gomez-Valderas E, Arad AD, Das S, Dunn JP, Ribeiro A, Glass LC, Lee CJ. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. PMID: 42119587.
  2. 2.Horn DB, Aronne LJ, Wharton S, Bays HE, Gomez-Valderas E, Arad AD, Sharma P, Dunn JP, Senyucel C, Lee CJ. Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN. Obesity (Silver Spring). 2025. PMID: 40916045.
  3. 3.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  5. 5.Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. PMID: 39536238.
  6. 6.Aronne LJ, Vincent RP, Klein KR, Brumm JF, Jouravskaya I, Cao D, Dimitriadis GK, Dunn JP. Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes. Obes Pillars. 2026. PMID: 42831032.
  7. 7.Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, Griffin R, Xie C, Valderas EG, Lee CJ, Ribeiro A, Hyman DM, Glass L, Xavier N. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
  8. 8.Marchetti M, Campisano G, Paragliola RM, Francomano D, Cipolloni V, Conforti A. Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review. Metabolites. 2026. PMID: 42941232.
  9. 9.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection. Prescribing information, revised 08/2026. DailyMed, U.S. National Library of Medicine (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  10. 10.Amioka M, Amioka H, Kinoshita H, Sairaku A, Nakano Y. Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. Diabetes Obes Metab. 2026. PMID: 42521631.

ATTAIN-MAINTAIN: Can a Pill Hold Weight Loss After Injections?

In a one-year trial, people who switched from tirzepatide or semaglutide to daily orforglipron kept more of their weight loss than those on placebo. No group stayed on the injection, so it can’t show whether the pill does as well as continuing it.

7 min read

Life After GLP-1: Maintenance Dosing, Microdosing, Tapering & What Happens When You Stop (2026 Decision Hub)

After reaching goal weight on Wegovy, Zepbound, Mounjaro or Ozempic, you have four paths: stay on a maintenance dose, space doses further apart, microdose, or taper off. Each has different evidence and weight-regain expectations.

9 min read

Zepbound Maintenance Dose After Goal Weight: SURMOUNT-4 Evidence Review

There is no FDA-approved Zepbound taper after goal weight. SURMOUNT-4 showed roughly half of lost weight returns within 52 weeks of stopping; SURMOUNT-MAINTAIN found a 5 mg step-down keeps most of it. Obesity is a chronic disease, not a finite course.

11 min read

GLP-1 Maintenance: Step-Down Dose Protocol — The Evidence

STEP-4 showed stopping semaglutide led to 11.6 kg regain in 48 weeks. But maintaining at a lower dose may preserve most of the loss while reducing cost and side effects. We review the published step-down evidence and the practical protocol.

11 min read

Weight Regain After Stopping Tirzepatide (Zepbound, Mounjaro): What the Trials Show

Stopping Zepbound or Mounjaro brings back most of the weight. In SURMOUNT-4, people regained 14% of body weight within a year of switching to placebo. Here's what the trials show on timing, who regains most, health markers, and the 5 mg step-down option.

11 min read

Can You Stay on a Low Dose of Wegovy? What the FDA Label Allows

The Wegovy label names 1.7 mg as a maintenance dosage for weight reduction in adults, not just a titration step — 2.4 mg is recommended but not mandatory. Here is the verbatim dosing language, why sub-1.7 mg doses are different, and what STEP 4 showed about reducing exposure.

8 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo

+ required membership

Get started →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $129/mo

“starting at” price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo

sale price

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →